Oral cancer - Molecular aberrations and tumor markers cellular aberrations

Harefuah

Volumn 142, Issue 4, 2003, Pages 272-276+317

  Nagler, Rafael ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Molecular aberrations; Oral cancer; SCC; Tumor markers

Indexed keywords

TUMOR MARKER;

CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CYTOLOGY; DISEASE SEVERITY; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; ISRAEL; MOLECULAR BIOLOGY; MOLECULAR PROBE; MOUTH CANCER; MOUTH CARCINOMA; NONHUMAN; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING;

CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; MOUTH NEOPLASMS; NEOPLASM METASTASIS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 0038298781     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Epstein JB & Scully C, Assessing the patient as risk for oral squamous cell carcinoma. SCD, 1997; 17: 120-128.
2. Raybaud-Diogène H, Tétu B, Morency R & al, p53 over-expression in head and neck squamous cell carcinoma: review of the literature, Oral Oncol, Eur J Cancer, 1996; 32B: 143-149.
3. Nylander K, Dabelsteen E & Hall PA, The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med, 2000; 29: 413-425.
4. Lippinan SM & Hong WK, Molecular markers of the risk of oral cancer. N Engl J Med, 2001; 344: 1323-1326.
5. Tralongo V, Rodolica V, Lucianai A & al, Prognostic factors in oral squamous cell carcinoma. A review of the literature. Anticancer Res, 1999; 19: 3505-3510.
6. Balaram P & Mennattoor G, Immunology of oral cancer « a review. Sing Dent J, 1996; 21: 36-41.
7. Byrne M, Prognostic value of various molecular and cellular features in oral squamous cell carcinomas. A review. J Oral Pathol Med 1991; 20: 413-420
8. Nagler RM, Laufer D, Kerner H & al, Squamous cell carcinoma of the tongue: the prevalence and prognostic roles of p53, Bcl-2, c-erbB2 and apoptotic rate as related to clinical and pathological characteristics in a retrospective study. Cancer Let, 2001 (In press).
9. Nagler RM, Barak M, Peled M & al, Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer, 1999; 85: 1018-1025.
10. Schwartz JL, Biomarkers and molecular epidemiology and chemoprevention of oral carcinogenesis. Crit Rev Oral Biol Med, 2000; 11: 92-122.
11. Dabelsteen E, Clausen H & Mandel U, Carbohydrate changes in squamous cell carcinoma. APMIS (Suppl). 1992; 100: 130-138.
12. Slootweg PJ, Suppressor protein p53 and its occurrence in oral tumours. Curr Top Pathol, 1996; 90: 179-200.
13. Nair U & Bartsch H, Metabolic polymorphisms as susceptibility markers for lung and oral cavity cancer. IARC Sci Pub, 2001; 154: 271-290.
14. Forastiere A, Kock W, Trotti A & Sidransky D, Head and neck cancer. N Engl J Med, 2001; 345: 1890-1900.
15. Bànkfalvi A & Piffkó J, Prognostic and predictive factors in oral cancer: the role of the invasive tumour front. J Oral Pathol Med, 2000; 29: 2291-2298.
16. Voravud N, Chemoprevention of head and neck cancer. J Med Assoc Thai, 1996; 79: 185-192.
17. Byrne M, Reibel J, Mandel U & Dabelsteen E, Expression of mucin type carbohydrates may supplement histologic diagnosis in oral premalignant lesions. J Oral Pathol Med, 1991; 20: 120-125.
18. Van Waes C & Carey TE, Overexpression of the A9 antigen/α6β4 integrin in heal and neck cancer. Otol Clin N Am, 1992; 25: 117-139.
19. Scully C & Burkhardt A, Tissue markers of potentially malignant oral epithelial lesions. J Oral Pathol Med, 1993; 22: 246-256.
20. Quak JJ, Schrijvers AFGJ, Brakkee JGP & al, Expression and characterization of two differentiation antigens in human stratified squamous epithelia and carcinomas. Int J Cancer, 1992; 50: 507-513.
21. Macluskey M & Ogden GR, An overview of the prevention of oral cancer and diagnostic markers of malignant change: 2. Markers of value in tumor diagnosis. Dent Update, 2000; 27: 148-152.
22. Burkhardt A, Oncogenes and growth factor receptors as diagnostic and prognostic markers in precancers and cancers of the oral mucosa. Cur Top Pathol, 1996; 90: 223-239.
23. de Vries N, van Zandwijk N & Pastoring U, Chemoprevention of head and neck and lung (pre) cancer. Rec Res Cancer Res, 1999; 151: 13-25.
24. Kim J & Shin DM, Biomarkers of squamous cell carcinoma of the head and neck. Histol Histopathol, 1997; 12: 205-218.
25. Dale BA, Thompson WB & Stern IB, Distribution of histidinerich basic protein: a possible keratin matrix protein in rat oral epithelium. Arch Oral Biol, 1982; 27: 535-545.
26. Grosso M, Lentini M, Bellizzi de Marco E & al, Immunohistochemical localization of filaggrin in benign and malignant lesions of the oral mucosa. Bas Appl Histochem, 1990; 34: 51-58.
27. Lotan R, Squamous cell differentiation markers in normal, premalignant and malignant epithelium: effects of retinoids. J Cell Biochem, 1993; Supplement 17F: 167-174.
28. Kowalski LP & Medina JE, Modal metastases: predictive factors. Otol Clinics of N Am, 1998, 31: 621-637.
29. Scully C, Field JK & Tanzawa H, Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinico-pathological applications. Oral Oncol, 2000; 36: 404-413.
30. Nagler R, Molecular aspects of oral cancer. Anticancer Res, 2003; 22.
31. Nagler R, Tissue and serum borne tumor markers of oral cancer - present and forthcoming therapeutic roles. Eur J Plastic Surg, 2002; 25: 235-242.